Cargando…

Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review

Ranibizumab is approved for the treatment of several macular disorders, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV), among others. The unaffordability of the innovator ranibizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shashikant, Sharma, Tanishq, Prasad, Somdutt, Gopalakrishnan, Mahesh, Chaturvedi, Alok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216589/
https://www.ncbi.nlm.nih.gov/pubmed/34155608
http://dx.doi.org/10.1007/s40123-021-00362-1
_version_ 1783710451864961024
author Sharma, Shashikant
Sharma, Tanishq
Prasad, Somdutt
Gopalakrishnan, Mahesh
Chaturvedi, Alok
author_facet Sharma, Shashikant
Sharma, Tanishq
Prasad, Somdutt
Gopalakrishnan, Mahesh
Chaturvedi, Alok
author_sort Sharma, Shashikant
collection PubMed
description Ranibizumab is approved for the treatment of several macular disorders, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV), among others. The unaffordability of the innovator ranibizumab among patients from developing countries such as India led to the development of the world’s first biosimilar ranibizumab, which is a cost-effective alternative that does not compromise efficacy and safety. Razumab™, developed and produced by Intas Pharmaceuticals Ltd., India, is the world’s first biosimilar of ranibizumab, and is approved in India for the treatment of various macular disorders, including wet AMD, DME, RVO and mCNV. The efficacy and safety of Razumab for the treatment of these macular disorders have been evaluated in both prospective and real-world retrospective studies. Razumab has shown an efficacy similar to that of the innovator ranibizumab, achieving improved visual acuity, as measured by the best corrected visual acuity, and reduction in the central macular thickness, leading to improved patient outcomes. The safety profile of Razumab is comparable to that of the innovator ranibizumab and is well tolerated without any new safety concerns. Here, we review the clinical and real-world data of Razumab in the treatment of macular disorders.
format Online
Article
Text
id pubmed-8216589
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-82165892021-06-23 Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review Sharma, Shashikant Sharma, Tanishq Prasad, Somdutt Gopalakrishnan, Mahesh Chaturvedi, Alok Ophthalmol Ther Review Ranibizumab is approved for the treatment of several macular disorders, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV), among others. The unaffordability of the innovator ranibizumab among patients from developing countries such as India led to the development of the world’s first biosimilar ranibizumab, which is a cost-effective alternative that does not compromise efficacy and safety. Razumab™, developed and produced by Intas Pharmaceuticals Ltd., India, is the world’s first biosimilar of ranibizumab, and is approved in India for the treatment of various macular disorders, including wet AMD, DME, RVO and mCNV. The efficacy and safety of Razumab for the treatment of these macular disorders have been evaluated in both prospective and real-world retrospective studies. Razumab has shown an efficacy similar to that of the innovator ranibizumab, achieving improved visual acuity, as measured by the best corrected visual acuity, and reduction in the central macular thickness, leading to improved patient outcomes. The safety profile of Razumab is comparable to that of the innovator ranibizumab and is well tolerated without any new safety concerns. Here, we review the clinical and real-world data of Razumab in the treatment of macular disorders. Springer Healthcare 2021-06-21 2021-09 /pmc/articles/PMC8216589/ /pubmed/34155608 http://dx.doi.org/10.1007/s40123-021-00362-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Sharma, Shashikant
Sharma, Tanishq
Prasad, Somdutt
Gopalakrishnan, Mahesh
Chaturvedi, Alok
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review
title Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review
title_full Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review
title_fullStr Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review
title_full_unstemmed Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review
title_short Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review
title_sort treatment landscape of macular disorders in indian patients with the advent of razumab™ (world’s first biosimilar ranibizumab): a comprehensive review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216589/
https://www.ncbi.nlm.nih.gov/pubmed/34155608
http://dx.doi.org/10.1007/s40123-021-00362-1
work_keys_str_mv AT sharmashashikant treatmentlandscapeofmaculardisordersinindianpatientswiththeadventofrazumabworldsfirstbiosimilarranibizumabacomprehensivereview
AT sharmatanishq treatmentlandscapeofmaculardisordersinindianpatientswiththeadventofrazumabworldsfirstbiosimilarranibizumabacomprehensivereview
AT prasadsomdutt treatmentlandscapeofmaculardisordersinindianpatientswiththeadventofrazumabworldsfirstbiosimilarranibizumabacomprehensivereview
AT gopalakrishnanmahesh treatmentlandscapeofmaculardisordersinindianpatientswiththeadventofrazumabworldsfirstbiosimilarranibizumabacomprehensivereview
AT chaturvedialok treatmentlandscapeofmaculardisordersinindianpatientswiththeadventofrazumabworldsfirstbiosimilarranibizumabacomprehensivereview